Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
August 01, 2024 16:05 ET | Athira Pharma, Inc.
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
lumos.png
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
August 01, 2024 16:05 ET | Lumos Pharma, Inc.
Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to...
Cytokinetics.png
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 01, 2024 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 31, 2024 it granted stock options to purchase an aggregate of...
outpace logo.png
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development
August 01, 2024 09:00 ET | Outpace Bio
Seattle, WA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- – Financing syndicate led by RA Capital Management with significant support from a world-class group of existing and new healthcare investors –...
enteralogo.png
Entera’s EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected
August 01, 2024 08:30 ET | Entera Bio Ltd.
JERUSALEM, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides and therapeutic proteins, today...
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
August 01, 2024 08:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
NodThera_logo.jpg
NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer
August 01, 2024 07:00 ET | NodThera
NodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer Greg brings over 25 years of public and private company leadership experience Philadelphia, PA, August 1, 2024 -...
JnanaTherapeutics_Logo_FullColor_RGB.png
Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
August 01, 2024 00:01 ET | Jnana Therapeutics, Inc.
Otsuka Pharmaceutical to acquire Jnana Therapeutics Inc.
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
July 31, 2024 21:15 ET | Ocugen
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and...
ocugen_4C_LOGO (002).png
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
July 31, 2024 16:15 ET | Ocugen
MALVERN, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and...